Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1
G Fätkenheuer, AL Pozniak, MA Johnson… - Nature medicine, 2005 - nature.com
G Fätkenheuer, AL Pozniak, MA Johnson, A Plettenberg, S Staszewski, AIM Hoepelman…
Nature medicine, 2005•nature.comWe assessed the efficacy and safety of 10-d monotherapy with the orally administered
CCR5 antagonist maraviroc in 63 HIV-1-positive individuals prescreened for the absence of
CXCR4-using virus. Maximum reduction in viral load occurred at a median of 10–15 d, with
a mean reduction of≥ 1.6 log10 copies/ml at all twice daily doses≥ 100 mg. These results
provide proof of concept that CCR5 antagonism is a viable antiretroviral therapeutic
approach.
CCR5 antagonist maraviroc in 63 HIV-1-positive individuals prescreened for the absence of
CXCR4-using virus. Maximum reduction in viral load occurred at a median of 10–15 d, with
a mean reduction of≥ 1.6 log10 copies/ml at all twice daily doses≥ 100 mg. These results
provide proof of concept that CCR5 antagonism is a viable antiretroviral therapeutic
approach.
Abstract
We assessed the efficacy and safety of 10-d monotherapy with the orally administered CCR5 antagonist maraviroc in 63 HIV-1-positive individuals prescreened for the absence of CXCR4-using virus. Maximum reduction in viral load occurred at a median of 10–15 d, with a mean reduction of ≥1.6 log10 copies/ml at all twice daily doses ≥100 mg. These results provide proof of concept that CCR5 antagonism is a viable antiretroviral therapeutic approach.
nature.com